Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Shionogi: Clinical Trials & FDA Approval Profile

Shionogi (Global / Institutional) sponsors 29 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 9 active protocols (6 recruiting now), 15 completed protocols, and 8 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)17.2%
Median Closed Enrollment vs National (145 pts)185 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Shionogi
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)29
Active Pipeline (Recruiting Now)9 (6)
Completed vs Stopped Early15 / 5 (17.2%)
Median Closed Actual Enrollment185 participants
Physical Hospital Site Disclosure99.9% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals8 (3 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Shionogi
Hospital Research SiteLocationShared Protocols
Fukushima Medical University HospitalFukushima6
Emory Winship Cancer InstituteAtlanta, GA5
Johns Hopkins Hospital and Kimmel Cancer CenterBaltimore, MD5

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Shionogi
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07123155Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)Phase IIRECRUITING
NCT07214571A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to SevePhase IIRECRUITING
NCT04110054Evaluation of S-600918 in Adults With Refractory Chronic CoughPhase IICOMPLETED
NCT04569084Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALSPhase IIITERMINATED
NCT05151471Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALSPhase IIITERMINATED

Explore interactive annual charts and M&A subsidiary rollups in the Shionogi Interactive Dossier, benchmark peers in Infectious Disease and Vaccines, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI